LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients
Comparison of two non-invasive models for advanced fibrosis detection in T2D and MASLD using LiverSTAT, FIB-4 and LSM (Saudi Arabia)
Evaluation of LIVERFASt for staging fibrosis in MASLD patients in NIDDK studies using liver biopsy
LIVERSTAT first-line screening tool: MAFLD patients outperformed standard-of-care FIB-4 (training/validation)
Recommended Clinical Care Pathway with FIB-4 underestimates the prevalence of Advanced Fibrosis, compared to sequential CCP with LIVERSTAT and LSM (NHANES)
LIVERSTAT as NIT for risk stratification for MAFLD — a single-centre study using liver biopsy as reference standard (Malaysia)
Fasting vs non-fasting: assessment of the impact on LIVERSTAT
LIVERFASt-LFS NIT for Fatty Liver Disease, for Primary Care Provider (PCP) screening
Assessment of Fatty Liver Disease using LIVERFASt in South-East Asia (real-world evidence)
Predictive Value of LIVERFASt, ARFI-FIB-4 to identify chronic Hepatitis B (CHB) — NUH Singapore cohort
